Thursday, September 25, 2008

Stocks you can invest in - LUPIN, OPTO CIRCUITS

LupinCMP: Rs 721Target Price: Rs 938Citigroup Global Markets has maintained its ‘buy’ recommendation on the stock saying the company’s initiative to build a global presence through small acquisitions and the buyout of a majority stake in Pharma Dynamics of South Africa would boost inorganic growth.

“This is the company’s third acquisition in FY09 after Hormosan (Germany) and a minority stake in Generic Health (Australia). We believe the small size has kept valuations reasonable & expect all deals to be EPS and RoI accretive from FY10,” said Citi in a note to its clients.

Citi has rated Lupin as ‘medium risk’ citing generic competition in Suprax (around 5% & 16% of sales & PBT) as the key reason. According to Citi, rising input costs due to Chinese government’s crackdown on environmentally unfriendly plants could hurt profitability. “Inability to effectively integrate the Kyowa acquisition could take a heavy toll on profitability as well as return ratios,” added the Citi note.

Opto CircuitsCMP: Rs 287.25Target Price: Rs 463Kotak Securities has maintained a ‘buy’ rating on the stock saying the valuations are very attractive considering the strong market positioning, potential introduction of new products, front end R&D set up (with the Criticare acquisition) and strong management.

The brokerage expects OCIL to register a 56.7% and 43.7% compounded growth in revenues and earnings, respectively over the next two years. It expects revenue growth of 73.9% to Rs 8.1 billion and net profit growth of 43.5% to Rs 1.9 billion in FY09.

“The key growth drivers for topline would likely to be stents business which is expected to grow at about 80% while non-invasive segment is expected to grow at 77%, mainly due to Criticare acquisition,” said the Kotak note. According to Kotak, net profit margin is likely to decline to 23.8% in FY10 as against 28.3% in FY08 mainly due to higher interest cost.

“The company has raised $52 million debt to fund the Criticare acquisition. We expect 43% and 44% growth in EPS in FY09 and FY10, respectively. In FY09, we expect EPS of Rs.20.2 while in FY10 we expect EPS of Rs.29,” the note added.---------------------------------------------------------------------------------------------------------

Mid Cap Stocks

Large Cap Stocks

Small Cap Stocks

Disclaimer:IndianStocksNews.com is in advisory role. The final decision of buying stocks and consequences based on our stock analysis and information is solely yours. Stock traders, investors and followers are cautioned that any forward-looking statements, stock tips and stock recommendations are not predictions and may be subject to change without notice. All the stock tips, stock research reports and other information on IndianStocksNews.com is strictly for reference purpose only and you are advised to do thorough analysis on your own before investing in stocks or trading stocks discussed here.